Abbott Labs (NYSE:ABT) is one of health care's do-everything stocks. It provides a solid dividend, offers plenty of growth opportunities through its resurgent nutrition business -- a business that grew sales by more than 8% through the year's first six months and has become the company's largest revenue source -- and has decades of experience of providing for investors.
All that hasn't come together in 2013, however. Abbott's stock has only just reached into the green on the year, and it's underperformed the market by a fair amount. After the recent health care investigations in China, Abbott and several of its rivals have seen their shares dive into the red.
Is this a big concern going forward for this sturdy stock? Below, Fool contributor Dan Carroll tells you what you need to know about Abbott's drop over the past three months and how you and your investments can capitalize on this timely dip.